US Healthcare Outlook Report 2022
This report can be delivered to the clients within 24 Hours
Health care in the US is provided by many distinct organizations such as 58% of community hospitals in the US are non-profit, 21% are government-owned, and 21% are for-profit. According to the World Health Organization, the US spent $9,403 on health care per capita, and 17.1% on health care as percentage of its GDP in 2014. Healthcare coverage is provided through a combination of private health insurance and public health coverage. Two most important healthcare coverage plans in US being Medicare and Medicaid.
DelveInsight’s, “US Healthcare Outlook 2022,” report provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in US. The report also identifies key trends in the healthcare market and provide insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of US.
As per DelveInsight analysis, US is headquarter to various major pharmaceutical and medical device companies of the world. Due to this, U.S. pharmaceutical market is the world's most important national market. The US alone holds over 45 % of the global pharmaceutical market, consisting of 784,626 companies.
US Healthcare Outlook
The U.S. is a country of 50 states covering a vast area of North America, with a population of 327.35 million inhabitants, distributed on a territory of 9.834 million square kilometers. In 2018, GDP growth for US was 2.9%. Healthcare is the largest source of work in the country, employing one in every eight citizens in the US.There is no universal healthcare coverage in US and government does not provide health benefits to citizens or visitors. When it comes to healthcare expenditures, the US tops the list, spending $10,224 per person. The aging population, rising rate of chronic diseases, and exponential advances in innovative, but costly, digital technologies continue to increase health care demand and expenditures.
The US Food and Drug Administration (FDA) is a Federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices among others.
US Industry Overview Chapter
Pharmaceutical
The US is the worldwide leader in per capita prescription drug spending. Many global pharmaceutical companies also have a presence in the U.S. Further, US is hub for various ongoing clinical trials. In the U.S., the majority of the pharmaceutical wholesaler business is concentrated in a few companies that hold the majority of the market share. There is also a large market in the U.S. for over-the-counter (OTC) medicines. Drugs for conditions like allergies and heartburn that required prescriptions in the past are now available for OTC sale. Use of generic drugs has also increased in recent years.
US government’s plan to implement of cost control policies along with tightening of rules by government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market are expected to impact the growth prospect of the U.S. pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the U.S. pharma market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug.
Medical Device
The US is the world's largest medical device market and it shows no signs of slowing. The US medical device industry was valued at $147.7 billion in 2016. There are more than 6,500 medical device companies in the U.S., mostly small and medium-sized enterprises (SMEs).
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in US.
US Healthcare Assessment Chapter
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage for Hepatitis B and Measles, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in US.
US: Market Access
Market access section of the US Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labelling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
The Department of Health and Human Services (HHS), at the federal level, is the primary agency responsible for regulating the health care system in the US. Each state, with a certain degree of self-governance, also has its own Department of Health (DoH) to implement state-level health policies. Health care provision and financing for those serving or formerly serving in the military are independently managed by either the Department of Defense (DoD) or the Department of Veterans’ Affairs (VA). These two departments finance 3% of the total health expenditure.
US: PESTLE Analysis
The report covers a thorough analysis of the country through PESTLE analysis tool and give political, economic, social, technological, legal and environmental aspects of healthcare industry.
Report Highlights
Health care in the US is provided by many distinct organizations such as 58% of community hospitals in the US are non-profit, 21% are government-owned, and 21% are for-profit. According to the World Health Organization, the US spent $9,403 on health care per capita, and 17.1% on health care as percentage of its GDP in 2014. Healthcare coverage is provided through a combination of private health insurance and public health coverage. Two most important healthcare coverage plans in US being Medicare and Medicaid.
DelveInsight’s, “US Healthcare Outlook 2022,” report provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in US. The report also identifies key trends in the healthcare market and provide insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of US.
As per DelveInsight analysis, US is headquarter to various major pharmaceutical and medical device companies of the world. Due to this, U.S. pharmaceutical market is the world's most important national market. The US alone holds over 45 % of the global pharmaceutical market, consisting of 784,626 companies.
US Healthcare Outlook
The U.S. is a country of 50 states covering a vast area of North America, with a population of 327.35 million inhabitants, distributed on a territory of 9.834 million square kilometers. In 2018, GDP growth for US was 2.9%. Healthcare is the largest source of work in the country, employing one in every eight citizens in the US.There is no universal healthcare coverage in US and government does not provide health benefits to citizens or visitors. When it comes to healthcare expenditures, the US tops the list, spending $10,224 per person. The aging population, rising rate of chronic diseases, and exponential advances in innovative, but costly, digital technologies continue to increase health care demand and expenditures.
The US Food and Drug Administration (FDA) is a Federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices among others.
US Industry Overview Chapter
Pharmaceutical
The US is the worldwide leader in per capita prescription drug spending. Many global pharmaceutical companies also have a presence in the U.S. Further, US is hub for various ongoing clinical trials. In the U.S., the majority of the pharmaceutical wholesaler business is concentrated in a few companies that hold the majority of the market share. There is also a large market in the U.S. for over-the-counter (OTC) medicines. Drugs for conditions like allergies and heartburn that required prescriptions in the past are now available for OTC sale. Use of generic drugs has also increased in recent years.
US government’s plan to implement of cost control policies along with tightening of rules by government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market are expected to impact the growth prospect of the U.S. pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the U.S. pharma market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug.
Medical Device
The US is the world's largest medical device market and it shows no signs of slowing. The US medical device industry was valued at $147.7 billion in 2016. There are more than 6,500 medical device companies in the U.S., mostly small and medium-sized enterprises (SMEs).
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in US.
US Healthcare Assessment Chapter
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage for Hepatitis B and Measles, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in US.
US: Market Access
Market access section of the US Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labelling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
The Department of Health and Human Services (HHS), at the federal level, is the primary agency responsible for regulating the health care system in the US. Each state, with a certain degree of self-governance, also has its own Department of Health (DoH) to implement state-level health policies. Health care provision and financing for those serving or formerly serving in the military are independently managed by either the Department of Defense (DoD) or the Department of Veterans’ Affairs (VA). These two departments finance 3% of the total health expenditure.
US: PESTLE Analysis
The report covers a thorough analysis of the country through PESTLE analysis tool and give political, economic, social, technological, legal and environmental aspects of healthcare industry.
Report Highlights
- Overview of the pharmaceutical and medical device markets
- An insightful review of the reimbursement and regulatory landscape, covering the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market
- US – Healthcare Outlook
- US – Healthcare Assessment
- US – Market Access
- US – Healthcare Market Perspectives
- US – Analyst Views
- What are business strategies and trends shaping and driving the US healthcare market?
- What are reimbursement and regulatory policies, pharmaceutical and medical device market segments and companies likely to impact the US healthcare market in the future?
- How to organize sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment and strategic partnership?
- How to identify, understand and capitalize on the opportunities and challenges in the US healthcare market?
- Pfizer
- Johnson & Johnson
- Roche
- AbbVie
- Amgen
- Novartis
- Merck & Co.
- Gilead Sciences
- Sanofi
- Bristol-Myers Squib
- B. Braun
1. KEY INSIGHTS
2. US AT A GLANCE
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. Key Reforms in US Healthcare Market
3.3. Healthcare Facility Administrative Structure
3.4. Governmental Healthcare Policy
3.5. Industry Overview
3.5.1. Pharmaceutical
3.5.1.1. Supply Channels
3.5.1.2. Major Players
3.5.1.3. Prescription VS OTC Drugs
3.5.2. Medical Device
3.5.2.1. Supply Chain
3.5.2.2. Major Distributors
3.6. Strategic Location
3.7. COVID-19 Update
3.8. Healthcare Technology Update
4. ASSESSMENT
4.1. Healthcare
4.1.1. Healthcare Facilities (Beds, Hospitals and Pharmacy)
4.1.2. Life Expectancy and Immunization Rate
4.1.3. Environmental Health (PM2.5 and CO2)
4.1.4. Healthcare Workforce (Physicians, Dentists and Nurses)
4.1.5. Healthcare Expenditure as share of GDP
4.1.6. Healthcare Expenditure
4.1.7. Out of Pocket Expenditure as share of current health expenditure
4.1.8. Pharmaceutical Imports and Exports
4.2. Economic
4.2.1. Gross Domestic Product
4.2.2. Inflation
4.2.3. Unemployment
4.2.4. Trade Association, US
4.2.5. Trade Fairs, US
5. MARKET ACCESS
5.1. Overview of Healthcare System Regulatory Bodies, US
5.2. Reimbursement Process, US
5.3. Health Insurance, US
5.4. Pricing Policies, US
5.5. Regulatory Landscape, US
5.5.1. Market Authorization for Pharmaceutical Products, US
5.5.2. Market Authorization for Medical Devices, US
5.5.3. Licensing Process for Pharmaceutical and Medical Device Manufacturing, US
5.5.4. Licensing Process for Pharmaceutical Exports and Imports, US
5.5.5. Intellectual Property Rights, US
5.5.5.1. Patent
5.5.5.2. Trademark
5.5.6. Clinical Trial Regulations, US
5.5.6.1. Pharmaceutical Clinical Trials Landscape, US
5.5.6.2. Medical Device Clinical Trials Landscape, US
5.5.7. Pharmaceutical Advertising Regulations, US
5.5.8. Medical Device Advertising Regulations, US
5.5.9. Pharmacy Regulations, US
5.5.10. Labeling and Packaging Regulations, US
6. US PESTLE ANALYSIS
7. DRIVER AND BARRIERS
8. APPENDIX
8.1. Research Methodology
8.1.1. Coverage
8.1.2. Secondary Research
9. REFERENCES
10. DELVEINSIGHT CAPABILITIES
11. DISCLAIMER
12. ABOUT DELVEINSIGHT
2. US AT A GLANCE
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. Key Reforms in US Healthcare Market
3.3. Healthcare Facility Administrative Structure
3.4. Governmental Healthcare Policy
3.5. Industry Overview
3.5.1. Pharmaceutical
3.5.1.1. Supply Channels
3.5.1.2. Major Players
3.5.1.3. Prescription VS OTC Drugs
3.5.2. Medical Device
3.5.2.1. Supply Chain
3.5.2.2. Major Distributors
3.6. Strategic Location
3.7. COVID-19 Update
3.8. Healthcare Technology Update
4. ASSESSMENT
4.1. Healthcare
4.1.1. Healthcare Facilities (Beds, Hospitals and Pharmacy)
4.1.2. Life Expectancy and Immunization Rate
4.1.3. Environmental Health (PM2.5 and CO2)
4.1.4. Healthcare Workforce (Physicians, Dentists and Nurses)
4.1.5. Healthcare Expenditure as share of GDP
4.1.6. Healthcare Expenditure
4.1.7. Out of Pocket Expenditure as share of current health expenditure
4.1.8. Pharmaceutical Imports and Exports
4.2. Economic
4.2.1. Gross Domestic Product
4.2.2. Inflation
4.2.3. Unemployment
4.2.4. Trade Association, US
4.2.5. Trade Fairs, US
5. MARKET ACCESS
5.1. Overview of Healthcare System Regulatory Bodies, US
5.2. Reimbursement Process, US
5.3. Health Insurance, US
5.4. Pricing Policies, US
5.5. Regulatory Landscape, US
5.5.1. Market Authorization for Pharmaceutical Products, US
5.5.2. Market Authorization for Medical Devices, US
5.5.3. Licensing Process for Pharmaceutical and Medical Device Manufacturing, US
5.5.4. Licensing Process for Pharmaceutical Exports and Imports, US
5.5.5. Intellectual Property Rights, US
5.5.5.1. Patent
5.5.5.2. Trademark
5.5.6. Clinical Trial Regulations, US
5.5.6.1. Pharmaceutical Clinical Trials Landscape, US
5.5.6.2. Medical Device Clinical Trials Landscape, US
5.5.7. Pharmaceutical Advertising Regulations, US
5.5.8. Medical Device Advertising Regulations, US
5.5.9. Pharmacy Regulations, US
5.5.10. Labeling and Packaging Regulations, US
6. US PESTLE ANALYSIS
7. DRIVER AND BARRIERS
8. APPENDIX
8.1. Research Methodology
8.1.1. Coverage
8.1.2. Secondary Research
9. REFERENCES
10. DELVEINSIGHT CAPABILITIES
11. DISCLAIMER
12. ABOUT DELVEINSIGHT
